全文获取类型
| 收费全文 | 1515129篇 |
| 免费 | 123126篇 |
| 国内免费 | 3737篇 |
专业分类
| 耳鼻咽喉 | 19784篇 |
| 儿科学 | 49353篇 |
| 妇产科学 | 42888篇 |
| 基础医学 | 214581篇 |
| 口腔科学 | 40233篇 |
| 临床医学 | 136780篇 |
| 内科学 | 305798篇 |
| 皮肤病学 | 35025篇 |
| 神经病学 | 127186篇 |
| 特种医学 | 57424篇 |
| 外国民族医学 | 468篇 |
| 外科学 | 226141篇 |
| 综合类 | 34537篇 |
| 现状与发展 | 4篇 |
| 一般理论 | 662篇 |
| 预防医学 | 119912篇 |
| 眼科学 | 34004篇 |
| 药学 | 106107篇 |
| 3篇 | |
| 中国医学 | 3505篇 |
| 肿瘤学 | 87597篇 |
出版年
| 2021年 | 12561篇 |
| 2019年 | 13383篇 |
| 2018年 | 18531篇 |
| 2017年 | 14204篇 |
| 2016年 | 15944篇 |
| 2015年 | 18053篇 |
| 2014年 | 25532篇 |
| 2013年 | 38011篇 |
| 2012年 | 51956篇 |
| 2011年 | 55083篇 |
| 2010年 | 32220篇 |
| 2009年 | 30977篇 |
| 2008年 | 51228篇 |
| 2007年 | 54202篇 |
| 2006年 | 54724篇 |
| 2005年 | 53331篇 |
| 2004年 | 50910篇 |
| 2003年 | 48706篇 |
| 2002年 | 46810篇 |
| 2001年 | 74060篇 |
| 2000年 | 75376篇 |
| 1999年 | 62651篇 |
| 1998年 | 18496篇 |
| 1997年 | 16665篇 |
| 1996年 | 16574篇 |
| 1995年 | 15764篇 |
| 1994年 | 14199篇 |
| 1993年 | 13402篇 |
| 1992年 | 46517篇 |
| 1991年 | 44079篇 |
| 1990年 | 42084篇 |
| 1989年 | 40118篇 |
| 1988年 | 36696篇 |
| 1987年 | 35850篇 |
| 1986年 | 33376篇 |
| 1985年 | 31892篇 |
| 1984年 | 24557篇 |
| 1983年 | 20778篇 |
| 1982年 | 13210篇 |
| 1981年 | 11697篇 |
| 1979年 | 21123篇 |
| 1978年 | 15108篇 |
| 1977年 | 12588篇 |
| 1976年 | 11773篇 |
| 1975年 | 11980篇 |
| 1974年 | 14284篇 |
| 1973年 | 13804篇 |
| 1972年 | 12846篇 |
| 1971年 | 11604篇 |
| 1970年 | 11034篇 |
排序方式： 共有10000条查询结果，搜索用时 515 毫秒
151.
152.
153.
154.
155.
Alexander Real Chierika Ukogu Divya Krishnamoorthy Nicole Zubizarreta Samuel K. Cho Andrew C. Hecht James C. Iatridis 《The spine journal》2019,19(2):225-231
Background Context
Low back pain (LBP) is a common complaint in clinical practice of multifactorial origin. Although obesity has been thought to contribute to LBP primarily by altering the distribution of mechanical loads on the spine, the additional contribution of obesity-related conditions such as diabetes mellitus (DM) to LBP has not been thoroughly examined.Purpose
To determine if there is a relationship between DM and LBP that is independent of body mass index (BMI) in a large cohort of adult survey participants.Study Design
Retrospective analysis of prospectively collected National Health and Nutrition Examination Survey (NHANES) data to characterize associations between LBP, DM, and BMI in adults subdivided into 6 subpopulations: normal weight (BMI 18.5–25), overweight (BMI 25–30), and obese (BMI >30) diabetics and nondiabetics. Diabetes was defined with glycohemoglobin A1c (HbA1c) ≥6.5%.Patient Sample
11,756 participants from NHANES cohort.Outcome Measures
Percentage of LBP reported.Methods
LBP reported in the 1999-2004 miscellaneous pain NHANES questionnaire was the dependent variable examined. Covariates included HbA1c, BMI, age, and family income ratio to poverty as continuous variables as well as race, gender, and smoking as binary variables. Individuals were further subdivided by weight class and diabetes status. Regression and graphical analyses were performed on the study population as a whole and also on subpopulations.Results
Increasing HbA1c did not increase the odds of reporting LBP in the full cohort. However, multivariate logistic regression of the 6 subpopulations revealed that the odds of LBP significantly increased with increasing HbA1c levels in normal weight diabetics. No other subpopulations reported significant relationships between LBP and HbA1c. LBP was also significantly associated with BMI for normal weight diabetics and also for obese subjects regardless of their DM status.Conclusions
LBP is significantly related to DM status, but this relationship is complex and may interact with BMI. These results support the concept that LBP may be improved in normal weight diabetic subjects with improved glycemic control and weight loss, and that all obese LBP subjects may benefit from improved weight loss alone. 相似文献156.
O. Morris M. Fairclough J. Grigg C. Prenant A. McMahon 《Journal of labelled compounds & radiopharmaceuticals》2019,62(1):4-23
Affinity peptide and protein‐ (APP) based radiotracers are an increasingly popular class of radiotracer in positron emission tomography (PET), which was once dominated by the use of small molecule radiotracers. Radiolabelled monoclonal antibodies (mAbs) are important examples of APPs, yet a preference for smaller APPs, which exhibit fast pharmacokinetics and permit rapid PET aided diagnosis, has become apparent. 18F exhibits favourable physical characteristics for APP radiolabelling and has been described as an ideal PET radionuclide. Notwithstanding, 18F radiolabelling of APP is challenging, and this is echoed in the literature where a number of diverse approaches have been adopted. This review seeks to assess and compare the approaches taken to 18F APP radiolabelling with the intention of highlighting trends within this expanding field. Generic themes have emerged in the literature, namely the use of mild radiolabelling conditions, a preference of site‐specific methodologies with an impetus for short, automated procedures which produce high‐yielding [18F]APPs. 相似文献
157.
158.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献159.
160.